Daewoong Pharmaceutical Co., Ltd (KRX:069620)
South Korea · Delayed Price · Currency is KRW 129,000
+1,000 (0.78%)
At close: Aug 7, 2026
Daewoong Pharmaceutical Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,592,199 | 1,570,891 | 1,422,683 | 1,375,329 | 1,280,092 | 1,152,976 |
Revenue Growth | 10.31% | 10.42% | 3.44% | 7.44% | 11.03% | 9.24% |
Gross Profit Gross Profit Growth | 820,609 | 822,532 | 734,168 | 687,108 | 638,095 | 543,749 |
Operating Income Operating Income Growth | 179,019 | 195,508 | 145,238 | 121,118 | 95,797 | 88,729 |
Net Income Net Income Growth | 199,862 | 195,856 | 24,735 | 121,739 | 42,240 | 24,506 |
Earnings Per Share EPS Growth | 17369.47 | 17021.64 | 2149.65 | 10655.61 | 3815.95 | 2226.87 |
EPS Growth | 419.47% | 691.83% | -79.83% | 179.24% | 71.36% | 86.18% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Pharmaceutical Manufacturing and Sales Pharmaceutical Manufacturing and Sales Growth | 1,600,769 | 1,458,090 | 1,409,520 | 1,316,601 | 1,184,293 |
Service Provision Service Provision Growth | 40,464 | 38,397 | 23,648 | 9,842 | 7,797 |
Other Other Growth | 3,027 | 7,193 | 8,262 | 5,232 | 1,465 |
Consolidation Consolidation Growth | -73,369 | -80,996 | -66,100 | -51,583 | -40,580 |
Total Total Growth | 1,570,891 | 1,422,683 | 1,375,329 | 1,280,092 | 1,152,976 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 168,031 | 172,801 | 116,347 | 137,685 | 140,651 | 173,734 |
Total Debt Total Debt Growth | 900,425 | 829,390 | 649,249 | 441,270 | 446,711 | 445,695 |
Net Cash (Debt) Net Cash Growth | -732,395 | -656,589 | -532,902 | -303,585 | -306,060 | -271,961 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -63650.47 | -57063.54 | -46314.03 | -26572.35 | -27649.69 | -24713.54 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 163,334 | 149,205 | 51,492 | 136,009 | 118,215 | 39,994 |
Capital Expenditures CapEx Growth | -245,620 | -191,534 | -155,145 | -109,338 | -65,227 | -29,088 |
Free Cash Flow Free Cash Flow Growth | -82,286 | -42,329 | -103,653 | 26,671 | 52,988 | 10,906 |
Free Cash Flow Growth | - | - | - | -49.67% | 385.84% | -85.36% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 51.54% | 52.36% | 51.60% | 49.96% | 49.85% | 47.16% |
Operating Margin | 11.24% | 12.45% | 10.21% | 8.81% | 7.48% | 7.70% |
Pretax Margin | 12.63% | 12.21% | 3.97% | 8.87% | 2.99% | 1.71% |
Profit Margin | 12.55% | 12.47% | 1.74% | 8.85% | 3.30% | 2.13% |
FCF Margin | -5.17% | -2.70% | -7.29% | 1.94% | 4.14% | 0.95% |
| Fiscal Year | Current | FY 2025 |
|---|---|---|
| Period Ending | Aug '26 Aug 8, 2026 | Dec '25 Dec 31, 2025 |
Dividend Per Share Dividend Per Share Growth | 600.000 | 600.000 |
Dividend Per Share Growth | 0% | - |
Dividend Yield | 0.47% | 0.35% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 7.43 | 10.12 | 58.80 | 11.04 | 41.54 | 66.85 |
Forward PE | 9.02 | 11.76 | 14.39 | 14.77 | 22.77 | 41.35 |
P/FCF Ratio | - | - | - | 50.39 | 33.11 | 150.21 |
PS Ratio | 0.93 | 1.26 | 1.02 | 0.98 | 1.37 | 1.42 |